Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
Colorectal Cancer, Metastasis
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring Colorectal cancer, metastatic, chemotherapy, randomized trial
Eligibility Criteria
Inclusion Criteria: Histologically confirmed metastatic colorectal adenocarcinoma Unresectable metastasis Bidimensionally measurable disease (World Health Organization [WHO] criteria) WHO performance status of 2 or less Adequate hematologic functions (neutrophil count, at least 1500 per cubic millimeter; and platelet count, at least 100,000 per cubic millimetre) Adequate renal function (serum creatinine, less than 125 micromol per liter) Adequate liver function (bilirubin, not more than 5 times the upper limit of normal) No previous chemotherapy other than previous adjuvant chemotherapy or concomitant chemoradiotherapy with 5-fluorouracil and leucovorin for the treatment of the primary tumor completed at least 6 months before inclusion Signed written inform consent Quality of life questionnaire (QLQ C-30) filled out Exclusion Criteria: Pregnant or breast - feeding women Impossibility of regular follow-up for psychological, social or geographical reason Severe cardiac, respiratory, renal or hepatic failure Active coronary heart disease Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study Central nervous system metastases Past history of second malignancies Another investigational drug Chronic inflammatory bowel disease Previous chemotherapy with irinotecan or oxaliplatin based regimens
Sites / Locations
- Institut Gustave-Roussy